Website_EBP-Cordant-368.png
Cordant Health Solutions™ provides innovative tools for monitoring behavioral health, chronic pain, and criminal justice cases. Our unique pharmacy and drug testing programs provide accurate, actionable results to protect prescribers, hold patients accountable, and optimize quality of life.
 
As a leader in quality standards, Cordant is committed to developing solutions for payers, clinicians, and organizations involved with substance use disorder, pain management, and criminal justice agencies. Cordant is one of the only health care companies that offers monitoring and risk assessment tools through its innovative drug testing options and full-service, high-touch pharmacies, which specialize in the complex management and dispensing of controlled substances. Cordant’s testing protocols and digital case-management tools help clients become more efficient and effective in using drug testing programs to monitor patient adherence, reduce risk, and improve patient outcomes.​

SERVICE ENDORSED by IHA:

Services surrounding the safe and effective prescribing of controlled substances as well as the support of addiction medicine providers.


CONTACT:

Regional Business Development Representative
12015 East 46th Avenue,  Suite 650
Denver, CO 80239
317-775-8577 
​12 FEB 2019

Feb. 22 Webinar – Testing for Alcohol Use 

Ethyl Glucuronide (EtG) and Ethyl Sulfate (EtS) are direct metabolites of ethanol that can be detected for up to 80 hours in urine after alcohol consumption. Testing for alcohol use can help to increase visibility into patient behavior, promote safety and improve adherence to treatment protocols, but only if you know how to accurately interpret the results. 

Join Cordant for an educational webinar with board-certified toxicologist Cynthia Whiteman as she discusses testing for alcohol use and answers commonly asked questions on drug test result interpretation as they relate to EtG/EtS testing.

Takeaways from this educational webinar will include: 
Understanding appropriate cut-offs 
Consumption vs. exposure
EtG/EtS in the diabetic patient
Commonly asked questions with result interpretation
Special considerations

Webinar details:
Date: Friday, February 22, 2019
Time: Noon ET
Presented by: Cynthia Whiteman MS, D-ABFT, Cordant Health Solutions Scientific and Operations Development Director - Behavioral Health



23 JAN 2019

Press Release: Cordant Announces Expanded Mental Health Monitoring Capabilities to Increase Medication Adherence for Chronic Conditions 


Cordant Health Solutions™, a leading provider of innovative tools for monitoring and managing behavioral health and chronic pain patients through its unique pharmacy and drug testing programs, now offers saliva testing that detects medications prescribed for mental health diagnoses as well as a simple cross-check for illicit or unprescribed medications that may cross-react or lead to harmful situations. 

According to the National Council for Behavioral Health, approximately 54.3 million adults in the U.S., or one in six, are prescribed a psychiatric drug to treat a mental illness. Yet research shows that less than half of those patients do not take their medications as prescribed. This non-adherence to a treatment plan limits the effectiveness of treatment and adds to the burden of illness for patients, families and employers nationwide.  Read the press release in its entirety.


29 MAR 2​​​018​

Pain Management Doctor Accomplishes What Many See As Impossible 

Last year, the CDC released guidelines regarding the prescribing of chronic opioids that have been adopted by many health insurance companies. These guidelines suggest that patients should be below a certain dosage of opioids due to the risk of potential unintentional overdose. In addition, in February 2018, the CMS proposed policy changes regarding limits on the cumulative daily dose of opioids dispensed to patients on Medicare Part D. 

Do clinicians and hospital systems continue to prescribe what is deemed unsafe or do they begin to taper their patients down, both of which have significant challenges? Many pain management providers would agree that it is nearly impossible to reduce a long-term patient’s opioid dose, especially to the extent needed to abide by these guidelines, yet that is exactly what many have been asked to do.  

The challenge of balancing the prescribing of pain medications for patients struggling with chronic pain against the continuing rise of opioid overdose leaves some clinicians opposed to prescribing opioids altogether. However, some doctors, like Anthony Mimms, MD, owner of Mimms Functional Rehabilitation in Indiana, are looking for solutions to this problem.  Read on.

13 FEB 2​​​018​

Webinar: The Fu​ndamentals of Toxicology Testing

​IHA Endorsed Business Partner Cordant will host a webinar reviewing the fundamentals of toxicology testing, including interpretation of results, on Febru​​ary 23 at no​on ET. Join toxicology expert, Damon Borg, Ph.D., to refresh your knowledge, gain new insights and review real examples of drug test results.  The webinar will cover:

  • Drug testing methods
  • Testing options: Point of Care, Immunoassay screening, LC-MS/MS and GC-MS/MS confirmations
  • Results interpretation ​

17 JAN  2018 

​​​​​Partnering, Not ​Policing: Using Data to Reduce Opioid Prescribing

In our current opioid crisis, clinicians have the very challenging job of balancing the prescribing of pain medications for patients struggling with chronic pain against the continuing rise of opioid overdoses. Many legitimate patients need access to these important medications, but some people try to get their hands on opioid medications with the intent to abuse or sell them.

Uncertainty about patient intent can lead some doctors to fear prescribing opioid medications at all. However, there is a solution that many clinicians and hospital systems see as the right balance, allowing them to practice medicine as they think appropriate while giving them necessary alerts when abuse or drug diversion is probable.

Anthony Mimms, MD and owner of Mimms Functional Rehabilitation in Indiana, started directing the majority of his chronic pain patients to use Cordant Pharmacy Solutions, which specializes in serving pain and substance use disorder patients.

“I chose Cordant because its unique model and detailed reporting supported my goal of appropriately reducing patients’ morphine equivalent dose (MED) levels,” said Mimms.

Cordant began by assessing the risk across Dr. Mimms’ patient population. This included reviewing, in partnership with the staff, the average MED levels of the practice and the state prescription drug monitoring program data, as well as providing reports with individual results and collective practice averages.

Referenced in the chart, in December of 2016, when Mimms’ patients first started using Cordant, almost sixty percent were at 121 MEDs or above, with forty percent of his patients over 201 MEDs. By October 2017 almost sixty percent of Mimms’ patients were between 50 and 90 MEDs and only fifteen percent had MEDs higher than 201.​


chart from 1-17-18 press release.PNG  

“Appropriate access to medication with the appropriate controls in place—that is the philosophy our pharmacy and integrated drug testing program is built around,” said Susan Sommer, president and CEO of Cordant. “Clinicians need to be able to practice medicine how they see fit, but they also need to have the right stopgaps in place. It’s not about policing patients with these reports, but when clinicians have easy access to the right information, it helps them determine the best path forward for their patients.”

Dr. Mimms launched his reduction plan with a broad communication strategy of forthright conversations with patients around the risks of long-term opioid use, the option of using alternative medications such as Lyrica and gabapentin while reducing MED levels, and the benefits of exercise and other important lifestyle choices.

Next Mimms and his team reviewed Cordant’s pharmacy reports, which detailed which patients were at higher risk for abuse and diversion and why, as well as gave him control over the process of helping them to safely and effectively bring down their prescribed opioid levels.

While he did lose some patients who refused changes to their treatment plan, he feels that both his patients and his practice are healthier for the modifications he has implemented.

With today’s opioid crisis escalating, calculating patient risk for abuse and diversion is critical, especially for pain patients taking prescribed opioid medications. One of the ways to calculate risk of overdose that is used by clinicians and regulators is to look at the patient’s MED level.

“Instead of figuring out and remembering what a risky dose is for each and every opioid, all opioids can be converted to an equivalent of one medication – morphine – which allows ease of calculating risk levels,” said Mimms. “For a comparison of opioid doses, a tool was developed to equate the many different opioids into one standard value, similar to how currency can be converted to a standard unit like the dollar. The standard opioid value is based on morphine and its potency, referred to as the morphine equivalent dose.”

Multiple studies have documented the increased risk of unintentional drug overdose as the MED level increases, making the consideration of MED levels extremely important in today’s treatment plans. State regulatory boards and agencies are establishing guidelines for prescribing and dispensing opioids to reduce risks such as misuse and overdose.

“Physicians are in a really hard place right now,” said Mimms. “We need to help our patients who need pain management treatment in order to function and have productive lives, but we know there is a national drug epidemic and that opioids are part of that problem. The only solutions we’re given from outside the industry are more recommendations or regulations. Cordant’s pharmacy is the first real solution I have seen since drug testing became an option for clinicians.”



29 AUG 2017